James Howard-Tripp on applying StageZero’s cancer diagnostics expertise to COVID-19 testing
InvestorIntel’s Tracy Weslosky talks with James Howard-Tripp, Chairman and CEO of StageZero Life Sciences Ltd. (TSX: SZLS), about StageZero’s early detection of cancer diagnostics and its new testing technology for COVID-19. Tracy observed, “You have one of the highest volume stock. You recently had a buy recommendation from Clarus Securities. What do you attribute all this recent attention to?” she asked.
“Fifteen years of work,” James replied.
“We are a cancer diagnostic company. So, when you deal with cancer everything needs to be absolutely precise,” James added. “When you move into another line, which is testing for COVID-19, you have to bring the exact same rigor to it. Everything that we do is to ensure that it is as precise as possible.” StageZero’s Aristotle testing platform can identify ten different types of cancer from a single blood test. “We believe that it will be in the market by year end. We are now completing the last of the validation,” James said.
To watch the complete interview, click here
Disclaimer: StageZero Life Sciences Ltd. is an advertorial member of InvestorIntel Corp.